CopyMark Law Group
4.9/5
Drawing for SB

USPTO serial 79446759

SB

Reviewed by CopyMark Law Group

Reg. 8481364Status 700Registered
Filing date
Status date
Registration date
Oct 6, 2026
Examiner
LUCAS, PATRICK T
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with SB?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael T. Smith

Michael T. Smith Birch Stewart Kolasch & Birch, LLP2600 Park Tower Drive, Suite 600Vienna, VA 22180United States

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic biomarker reagents for medical purposes; medicines for human purposes, namely, medicines for the treatment of cardiovascular and cerebrovascular diseases, central nervous system stimulants, tumor suppressing agents, diagnostic agents for medical purposes, pharmaceutical agents affecting peripheral nervous system, medicines for intestinal disorders, medicines for dental purposes, medicines for alleviating constipation, medicines for adjusting the menstrual cycle, medicines for the treatment of gastrointestinal diseases, anti-cancer preparations, medicaments for promoting recovery from tendon and muscle injuries and disorders and sports related injuries, blood and immune system diseases, nervous system degenerative and traumatic disorders, metabolic and endocrine system diseases, cardiovascular and retinal degenerative diseases, bone, joint and cartilage injuries, and tumors; immunostimulants; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer, biological preparations for use in cell cultures for medical purposes, stem cells for medical purposes, cells for medical use, biologics in the nature of cells for medical use, antibody reagents used for the detection of antigens in cells and tissue for medical purposes, biological preparations for the treatment of blood and immune system diseases, nervous system degenerative and traumatic disorders, metabolic and endocrine system diseases, cardiovascular and retinal degenerative diseases, bone, joint and cartilage injuries, and tumors; collagen for medical purposes; drugs for medical purposes, namely, the treatment of cancer, blood and immune system diseases, nervous system degenerative and traumatic disorders, metabolic and endocrine system diseases, cardiovascular and retinal degenerative diseases, bone, joint and cartilage injuries, and tumors; enzymes for medical purposes; enzyme preparations for medical purposes; pharmaceutical preparations, namely, anti-epileptic pharmaceutical preparations, cardiovascular pharmaceutical preparations, pharmaceutical preparations for treating hypertension, pharmaceutical preparations for treating diabetes, pharmaceutical preparations for suppressing tumors, pharmaceutical preparations for peripheral nervous system, pharmaceutical preparations for the central nervous system, pharmaceutical preparations used in organ transplantation, pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for cellular therapy for the treatment of blood and immune system diseases, nervous system degenerative and traumatic disorders, metabolic and endocrine system diseases, cardiovascular and retinal degenerative diseases, bone, joint and cartilage injuries, and tumors; organotherapy preparations; nutraceutical preparations for use as a dietary supplement for therapeutic or medical purposes; vaccines; stem cells for veterinary purposes; transplants, being implants comprised of living tissues; blood plasma; hair serums for medical purposes; skin serums for medical purposes; lip serums for medical purposes; biological tissue cultures for veterinary purposes; medicines for veterinary purposes, namely, medicines for the treatment of cancer, stem cells for veterinary purposesACTIVE—
042Chemical research; product quality testing; scientific research in the nature of conducting clinical trials for others; medical research laboratory services; medical research; stem cell research services; biological cloning services; biological research; genetic testing for scientific research purposes; bacteriological researchACTIVE—
044Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical clinic services; convalescent home services; services of a psychologist; rental of sanitary installations; stem cell therapy services; cognitive therapy services; meditation therapy services; nutritional therapy services; speech pathology therapy services; hormone replacement therapy services; intravenous (IV) hydration therapy services; bodywork therapy services, namely, craniosacral, acupressure, massage, structural integration and movement therapy; physical therapy services for the treatment of blood and immune system diseases, nervous system degenerative and traumatic disorders, metabolic and endocrine system diseases, cardiovascular and retinal degenerative diseases, bone, joint and cartilage injuries, and tumors; telemedicine services; massage; health care consultancy; health counselingACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 6, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 6, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 18, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 18, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 12, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 21, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 13, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 13, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 13, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 4, 2026RFNTREFUSAL PROCESSED BY IB—
May 15, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 14, 2026RFRRREFUSAL PROCESSED BY MPU—
Mar 29, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 28, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 28, 2026DOCKASSIGNED TO EXAMINER—
Mar 27, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 27, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 26, 2026REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance